Haemophilus influenzae (n ‫؍‬ 1,077) and Moraxella catarrhalis (n ‫؍‬ 503) from 27 U.S. and 7 Canadian medical centers were characterized as part of the SENTRY Antimicrobial Surveillance Program. Overall prevalences of ␤-lactamase production were 33.5% in H. influenzae and 92.2% in M. catarrhalis with no differences noted between isolates recovered in the United States and those from Canada. Among a total of 21 different antimicrobial agents tested, including six cephalosporins, a ␤-lactamase inhibitor combination, three macrolides, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, chloramphenicol, five fluoroquinolones, and quinupristin-dalfopristin, resistance rates of >5% with H. influenzae were observed only with cefaclor (12.8%) and TMP-SMX (16.2%).
The empiric management of community-acquired respiratory tract infections such as otitis media, sinusitis, acute purulent exacerbation of chronic bronchitis, and community-acquired pneumonia has been complicated by the emergence of high rates of antimicrobial resistance in three major pathogens: Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Of these, only S. pneumoniae has been the focus of numerous recent studies, perhaps because of its greater virulence and the fact that antimicrobial resistance in this pneumococcus has reached extraordinary levels over a very short period in North America (1, 2, 7, 12, 26) . However, H. influenzae and M. catarrhalis remain a problem in the context of antimicrobial resistance.
At least 11 systematic, nationwide surveillance studies of antimicrobial resistance in H. influenzae have been conducted in North America during the past 15 years, eight in the United States (2, 6, 9, 10, 17, 18, 23, 30) and three in Canada (24, 25, 27) . The earliest of these studies, performed from 1983 to 1984, characterized 3,356 clinical isolates of H. influenzae from 22 U.S. medical centers and revealed an overall prevalence of ␤-lactamase-mediated ampicillin resistance of 15.2% (9) . The two most recent studies, both conducted in the United States from 1994 to 1995, revealed overall rates of ␤-lactamase production of 35.6% among 1,605 isolates from 30 centers and 36.1% among 2,278 strains from 187 institutions (6, 17) . In general, the prevalences of ␤-lactamase-producing isolates of H. influenzae in the United States and Canada have been roughly comparable. Resistance to other antimicrobial agents such as the cephalosporins, ␤-lactamase inhibitor combinations, macrolides, tetracycline, chloramphenicol, trimethoprim-sulfamethoxazole (TMP-SMX), and the fluoroquinolones has remained relatively uncommon with H. influenzae in North America (2, 6, 17, 30) .
␤-Lactamase-mediated resistance to penicillins in M. catarrhalis is even more common than in H. influenzae. Four large, multicenter, national surveillance studies conducted in the United States during the 1990s revealed an overall rate of ␤-lactamase production in M. catarrhalis of between 90.1 and 96.8% (2, 8, 18, 30) . Resistance to other antimicrobials has not emerged as a significant problem with this organism.
The question arises: what is the current prevalence of antimicrobial resistance in respiratory tract isolates of H. influenzae and M. catarrhalis in North America? In an attempt to answer this question, a 5-month, multicenter surveillance study was performed in the United States and Canada during 1997. This investigation was conducted as part of the SENTRY Antimicrobial Surveillance Program, a prospective, longitudinal, multinational study aimed at tracking the emergence of antimicrobial resistance worldwide.
During the 5-month period from February through June 1997, a total of 837 isolates of H. influenzae and 374 isolates of M. catarrhalis were recovered in the clinical microbiology laboratories of 27 medical centers in the United States (Table 1) . A total of 240 isolates of H. influenzae and 129 isolates of M. catarrhalis were recovered in the laboratories of seven Canadian hospitals during the same period ( Table 1 ). All isolates were transported to the coordinating laboratory, the University of Iowa College of Medicine (Iowa City), where stock cultures were prepared in defibrinated rabbit blood and frozen at Ϫ70°C. Only organisms judged to be the cause of defined respiratory tract infections in outpatients were included in this study. Criteria in place at individual laboratories were used to assess clinical significance. Frozen isolates were thawed and subcultured twice on 5% sheep blood agar plates prior to further characterization.
At the coordinating study center, the identity of isolates was confirmed by using conventional criteria (4, 20) and the MICs of 21 antimicrobial agents were determined by a reference broth microdilution method (21). The following antimicrobials were tested: amoxicillin, amoxicillin-clavulanate, cefaclor, cefuroxime, cefixime, cefpodoxime, cefotaxime, cefepime, azithromycin, clarithromycin, erythromycin, chloramphenicol, tetracycline, TMP-SMX, rifampin, ciprofloxacin, levofloxacin, gatifloxacin, sparfloxacin, trovafloxacin, and quinupristin-dalfopristin. Dehydrated microdilution trays were obtained commercially (Dade-MicroScan, Inc., Sacramento, Calif.). Drugs were tested over concentration ranges that yielded on-scale MICs with Ͼ98% of organism-antimicrobial combinations. Haemophilus test medium broth, 100 l per well, was employed as a growth medium for H. influenzae during MIC determinations (11, 19, 21) . Cation-adjusted Mueller-Hinton broth, 100 l per well, was used in MIC determinations for M. catarrhalis (21). The final inoculum concentration was approximately 5 ϫ 10 5 CFU/ml. Trays were incubated for 20 to 24 h at 35°C in ambient air prior to MIC determinations. MICs were defined as the lowest concentration of drug that yielded no visible evidence of growth of the test organism. H. influenzae ATCC 49247 and ATCC 49766 were used as control organisms throughout this study. Production of ␤-lactamase was assessed by use of the Cefinase disk test (Becton Dickinson Microbiology Systems, Cockeysville, Md.).
A total of 1,077 isolates of H. influenzae were characterized, 837 from 27 U.S. medical centers and 240 from seven Canadian institutions ( Table 1 ). The overall prevalences of ␤-lactamase-producing strains were 34.2% in the United States and 31.3% in Canada (P ϭ 0.09). Collectively in North America, 33.5% of respiratory tract isolates of H. influenzae produced ␤-lactamase. Among centers with at least 20 isolates, rates of ␤-lactamase production varied between 18.2 and 50.0% (Table  1) .
Results of MIC determinations with 14 selected antimicrobial agents against this collection of H. influenzae are summarized in Table 2 . Isolates from U.S. and Canadian medical centers were grouped together for purposes of this analysis because when they were analyzed separately, no significant differences were noted between the two countries (data not shown). Among ␤-lactam agents, resistance was not detected with cefixime (MIC at which 90% of the isolates are inhibited [MIC 90 ], 0.12 g/ml), cefpodoxime (MIC 90 , 0.25 g/ml), cefo- Among the five fluoroquinolones examined in this study, i.e., ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, and gatifloxacin, a nearly uniform activity was observed for study strains of H. influenzae for which the MIC 50 s, MIC 90 s, and modal MICs were Յ0.06 g/ml. The highest MIC obtained with any of these agents was 0.25 g/ml (data not shown). The combination quinupristin-dalfopristin was characterized by a MIC 50 , MIC 90 , and modal MIC of 4, 8, and 4 g/ml, respectively.
Amoxicillin MICs for all of the 361 ␤-lactamase-producing isolates in this study were Ն4 g/ml; for only 1 of 716 ␤-lactamase-negative isolates (i.e., 0.1%) was the amoxicillin MIC 8 g/ml, indicating resistance. The amoxicillin-clavulanate MIC for this isolate was 8/4 g/ml. Two ␤-lactamase-positive isolates of H. influenzae (i.e., 0.2%) that were resistant to amoxicillin-clavulanate (MICs of Ն8/4 g/ml) were recovered in this study. The amoxicillin-clavulanate MICs for these two strains were confirmed by repeat testing. Other than amoxicillin, of the antimicrobial agents examined in this study, only cefaclor activity appeared to be adversely influenced by ␤-lactamaseproduction in H. influenzae. The following cefaclor MICs were obtained with ␤-lactamase-positive and -negative strains, respectively: MIC 50 s, 8 and 2 g/ml; MIC 90 s, Ͼ32 and 8 g/ml; modal MICs, 8 and 2 g/ml; susceptibility rates, 54.0 and 92.5%; and resistance rates, 32.7 and 2.5%. Essentially comparable in vitro activity was noted with all other agents when the results obtained with these agents were compared with ␤-lactamase-positive and ␤-lactamase-negative strains (data not shown).
A total of 503 isolates of M. catarrhalis were characterized in this study, 374 from the United States and 129 from Canada ( Table 1 ). The overall prevalence of ␤-lactamase production was 92.2% and very uniform between the two countries, i.e., 92.0% in the United States and 93.0% in Canada. MICs are listed for 14 selected antimicrobial agents in Table 3 . All of these compounds were consistently active against this collection of M. catarrhalis isolates. In addition, the five fluoroquinolones examined in this study were uniformly active against M. catarrhalis at very low concentrations. The MIC 90 s of these agents were as follows: ciprofloxacin, Յ0.03 g/ml; levofloxacin, Յ0.05; gatifloxacin, Յ0.03 g/ml; sparfloxacin, Յ0.12 g/ml; and trovafloxacin, Յ0.03 g/ml. The highest MICs obtained with each of these fluoroquinolones were 1, 2, 1, 0.5, and 0.5 g/ml, respectively (data not shown). The MIC 50 and MIC 90 of quinupristin-dalfopristin were both 0.5 g/ml (range, Յ0.06 to Ͼ8 g/ml). Amoxicillin MICs for the 464 ␤-lactamase-producing isolates of M. catarrhalis in this study varied substantially (range, Յ0.06 to Ͼ8 g/ml). The number of ␤-lactamase-positive isolates for which amoxicillin MICs were Յ1, 2, 4, and Ն8 g/ml were 103 (22.2%), 61 (13.1%), 89 (19.2%), and 211 (45.5%), respectively. By contrast, amoxicillin-clavulanate MICs were Յ1 g/ml for all 464 ␤-lactamase-positive isolates.
The results of this survey indicate that the prevalence of ␤-lactamase production among respiratory tract isolates of H. influenzae (i.e., 33.5%) may have leveled off in North America. Two recent multicenter U.S. surveillance studies which emphasized respiratory tract isolates of H. influenzae, both conducted in 1994 to 1995, revealed overall rates of ␤-lactamase production of 35.6 and 36.1% (6, 11) . As has been observed in previous studies (6, 17, 24, 25, 27) , only small differences were noted in the current investigation between the rates of ␤-lactamase production in the United States (34.2%) and Canada (31.3%). Amoxicillin resistance among ␤-lactamasenegative strains and amoxicillin-clavulanate resistance among ␤-lactamase-positive strains, as has been described recently (6) , were uncommon in the current survey (i.e., 0.1 and 0.2%, respectively).
Among the 19 other antimicrobial agents examined in this study, only two compounds were characterized by resistance rates greater than 5% in H. influenzae, cefaclor (12.8%) and TMP-SMX (16.2%). With cefaclor, much higher resistance rates were noted in ␤-lactamase-producing isolates than in organisms that lacked ␤-lactamase production. The actual clinical implications of these findings remain to be defined. Several recent studies have questioned the clinical predictive value of MICs obtained with oral antimicrobial agents used to treat localized respiratory tract infections caused by H. influenzae (5, 15, 16) .
The results of this study corroborate the findings of previous investigators regarding the high prevalence of ␤-lactamase production among respiratory tract isolates of M. catarrhalis (2, 8, 18, 30) . Overall, 92.2% of 503 isolates produced ␤-lactamase, 92.0% in the United States and 93.0% in Canada. Amoxicillin MICs were Յ1 g/ml for 22.2% of ␤-lactamaseproducing isolates, which probably would be considered to indicate susceptibility. Similar observations have been made previously with M. catarrhalis and may reflect the fact that some ␤-lactamase-positive strains produce a BRO-2 enzyme (3, 28, 29) . This enzyme is produced in small amounts, remains tightly cell associated, and has a low affinity for aminopenicillins such as ampicillin and amoxicillin. Ampicillin and amoxicillin MICs for BRO-2-producing strains of M. catarrhalis are typically found to be low (3, 28) and represent one example of where production of a ␤-lactamase does not actually result in ampicillin-amoxicillin resistance. All ␤-lactamase-producing strains of M. catarrhalis were inhibited by concentrations of Յ4/2 g of amoxicillin-clavulanate per ml.
The 19 remaining antimicrobial agents examined in this investigation were almost uniformly active against M. catarrhalis (Table 3 ). The activities of these agents were assessed based on breakpoints advocated by the National Committee for Clinical Laboratory Standards (NCCLS) for use in testing nonfastidious bacteria that grow well on unsupplemented MuellerHinton medium, as is the case with M. catarrhalis (13) . Two previous studies demonstrated that such breakpoints were applicable to M. catarrhalis (13, 14) . Based on these breakpoints, resistance was observed with only three compounds (cefaclor, cefotaxime, and TMP-SMX) and then only with a single isolate each.
In conclusion, in this multicenter, North American surveillance study, 33.5 and 92.2% of community-acquired respiratory tract isolates of H. influenzae and M. catarrhalis, respectively, were found to produce ␤-lactamase. As a result of ␤-lactamase production, amoxicillin resistance with these two organisms is common. In contrast, with the exception of cefaclor and TMP-SMX tested against H. influenzae, all of the alternative antimicrobials examined in this investigation were nearly uniformly active against both organisms. Because of the longitudinal nature of the SENTRY Antimicrobial Surveillance Program, we will continue to track the susceptibility trends of both H. influenzae and M. catarrhalis in North America over the next several years.
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